Summary
Vertex Pharmaceuticals Inc. is focused on the development and commercialization of small molecule drugs for serious diseases, with its lead candidate, telaprevir, a protease inhibitor for Hepatitis C (HCV) infection, being a significant area of investment. The company is progressing telaprevir through late-stage clinical trials for genotype 1 HCV and anticipates an NDA submission in the second half of 2010. Another key focus is VX-770, a drug candidate for cystic fibrosis (CF), for which a registration program is expected to begin in the first half of 2009. Vertex also has a diversified pipeline including other HCV drug candidates, a JAK3 inhibitor for immune-mediated inflammatory diseases, and oncology drug candidates through collaborations. Financially, Vertex reported a net loss for the year ended December 31, 2008, reflecting substantial ongoing investment in research and development. The company ended 2008 with a strong cash position and continues to explore financing options to support its extensive development activities.
Financial Highlights
27 data points| Revenue | $175.50M |
| R&D Expenses | $516.91M |
| SG&A Expenses | $101.29M |
| Operating Expenses | $638.21M |
| Operating Income | -$462.71M |
| Interest Expense | $13.47M |
| Net Income | -$459.85M |
| EPS (Basic) | $-3.27 |
| EPS (Diluted) | $-3.27 |
| Shares Outstanding (Basic) | 140.56M |
| Shares Outstanding (Diluted) | 140.56M |
Key Highlights
- 1Vertex Pharmaceuticals is advancing telaprevir, its lead drug candidate for Hepatitis C, into late-stage Phase 3 clinical trials (ADVANCE, REALIZE) with an anticipated NDA submission in H2 2010.
- 2The company is also developing VX-770 for cystic fibrosis, targeting patients with the G551D mutation, and plans to initiate a registration program in H1 2009.
- 3Financial performance for the year ended December 31, 2008, showed a net loss of $459.9 million, with total revenues of $175.5 million, driven by significant investments in research and development.
- 4Vertex ended 2008 with a robust cash position of $832.1 million, providing substantial runway for ongoing and future development programs.
- 5The company's strategy includes completing telaprevir development, establishing leadership in HCV treatment, developing its CF drug candidates, and investing in research across multiple therapeutic areas.
- 6Vertex relies on strategic collaborations, such as with Janssen for telaprevir in territories outside North America, to support its development and commercialization efforts.